Author

Nancy S. Wang

Cleveland Clinic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 1 Assay:structural biology· 1

Frequent Co-Authors

Christopher M. GoinsiD· 3 shared Jesse A. CokeriD· 3 shared Shaun R. StaufferiD· 3 shared Todd RomighiD· 3 shared Paul M. PolzeriD· 2 shared A. Abigail Lindsey· 1 shared Abhishek A. ChakrabortyiD· 1 shared Alexander EarsleyiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Christopher M. GoinsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma

Jesse A. Coker, Steven R. Martinez, Sang Hoon Han, Anthony R. Sloan, Amit Kumar Gupta, George Bukenya, Paul M. Polzer, James H. Ramos, Emma G. Rico, Annabella Rico, A. Abigail Lindsey, Tanvi Navadgi, Natalie Reitz, Todd Romigh, Jonathan Macdonald, , Shaun R. Stauffer

This study develops triazole-based WDR5 inhibitors that show improved brain penetration and antiproliferative activity against glioblastoma CSCs, with synergistic effects when combined with ATAD2 inhibitors.

JCI Insight · May 5, 2026Peer-reviewedCancer Biology

Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch Variability

Jesse Coker, Rong Sun, Paul M. Polzer, Todd Romigh, Christopher M. Goins, Nancy S. Wang, Jae U. Jung, Shaun R. Stauffer

The paper identifies false positive inhibitors of NSP14 ExoN due to contaminating divalent cations, highlighting challenges in fragment-based drug development for this target.

ACS Chemical Biology · Feb 16, 2026Peer-reviewedBiochemistry

Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer

Pooneh Koochaki, Biao Qiu, Jesse A. Coker, Alexander Earsley, Nancy S. Wang, Todd Romigh, Christopher M. Goins, Carleigh Salem, Dehui Mi, Emily Days, Joshua A. Bauer, Shaun R. Stauffer, Olga Boudker, Abhishek A. Chakraborty

This study determines the cryo-EM structure of SLC1A1 bound to an inhibitor, identifies its binding mechanism, and develops improved inhibitors with enhanced cytotoxicity in kidney cancer cells.

bioRxiv · Jul 3, 2025 · PreprintCancer Biology